ArcticZymes Technologies

ArcticZymes Technologies leverages its unique Arctic environment to discover and develop extremozymes—enzymes from extremophilic microorganisms—that function in non-standard conditions where conventional enzymes fail. With over 30 years of expertise, the company has pioneered industry breakthroughs like the first commercially available salt-active nuclease and COD UNG, targeting the high-growth markets of gene therapy, viral vector manufacturing, and molecular diagnostics. As a publicly traded company on the Oslo Stock Exchange, it focuses on providing GMP-grade enzymatic solutions to improve efficiency and reduce costs in biopharmaceutical production.

Platform for discovering and engineering extremozymes—cold-adapted enzymes from Arctic microorganisms—that function optimally in high-salt and low-temperature conditions, enabling efficient biomanufacturing and molecular research.

Competes with large, diversified reagent suppliers like Thermo Fisher and Merck, as well as specialized enzyme firms like New England Biolabs. Its primary differentiation is its focus on extremozymes, particularly salt-active nucleases, which offer unique performance advantages in high-salt bioprocessing conditions where competitors' standard enzymes are less effective.